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Abstract
Although CRISPR-Cas9 nucleases are widely used for genome editing1, 2, the range of sequences 
that Cas9 can recognize is constrained by the need for a specific protospacer adjacent motif 
(PAM)3–6. As a result, it can often be difficult to target double-stranded breaks (DSBs) with the 
precision that is necessary for various genome editing applications. The ability to engineer Cas9 
derivatives with purposefully altered PAM specificities would address this limitation. Here we 
show that the commonly used Streptococcus pyogenes Cas9 (SpCas9) can be modified to 
recognize alternative PAM sequences using structural information, bacterial selection-based 
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directed evolution, and combinatorial design. These altered PAM specificity variants enable robust 
editing of endogenous gene sites in zebrafish and human cells not currently targetable by wild-
type SpCas9, and their genome-wide specificities are comparable to wild-type SpCas9 as judged 
by GUIDE-Seq analysis7. In addition, we identified and characterized another SpCas9 variant that 
exhibits improved specificity in human cells, possessing better discrimination against off-target 
sites with non-canonical NAG and NGA PAMs and/or mismatched spacers. We also found that 
two smaller-size Cas9 orthologues, Streptococcus thermophilus Cas9 (St1Cas9) and 
Staphylococcus aureus Cas9 (SaCas9), function efficiently in the bacterial selection systems and 
in human cells, suggesting that our engineering strategies could be extended to Cas9s from other 
species. Our findings provide broadly useful SpCas9 variants and, more importantly, establish the 
feasibility of engineering a wide range of Cas9s with altered and improved PAM specificities.
CRISPR-Cas9 nucleases enable efficient genome editing in a wide variety of organisms and 
cell types1, 2. Target site recognition by Cas9 is programmed by a chimeric single guide 
RNA (sgRNA) that encodes a sequence complementary to a target protospacer5, but also 
requires recognition of a short neighboring PAM3–6. SpCas9, the most robust and widely 
used Cas9 to date, primarily recognizes NGG PAMs and is consequently restricted to sites 
that contain this motif5, 8. It can therefore be challenging to implement genome editing 
applications that require precision, such as: homology-directed repair (HDR), which is most 
efficient when DSBs are placed within 10–20 bps of a desired alteration9–11; the 
introduction of variable-length insertion or deletion (indel) mutations into small size genetic 
elements such as microRNAs, splice sites, short open reading frames, or transcription factor 
binding sites by non-homologous end-joining (NHEJ); and allele-specific editing, where 
PAM recognition might be exploited to differentiate alleles.
One potential solution to address targeting range limitations would be to engineer Cas9 
variants with novel PAM specificities. A previous attempt to alter SpCas9 PAM specificity 
mutated R1333 and R1335 residues that contact the guanine nucleotides at the second and 
third PAM positions; however, the R1333Q/R1335Q variant failed to cleave a site harboring 
the expected NAA PAM in vitro12. Using a human cell-based U2OS EGFP reporter gene 
disruption assay in which nuclease-induced indels lead to loss of fluorescence13, 14, we 
confirmed that an R1333Q/R1335Q SpCas9 variant failed to efficiently cleave target sites 
with NAA PAMs (Fig. 1a). Additionally, we found that single R1333Q and R1335Q 
variants each failed to efficiently cleave target sites containing the expected NAG and NGA 
PAMs, respectively (Fig. 1a), suggesting that re-engineering PAM specificity might require 
additional mutations.
To identify such mutations, we adapted a bacterial selection system (hereafter referred to as 
the positive selection) previously used to study properties of homing endonucleases15, 16. In 
our adaptation of this system, survival is enabled by Cas9-mediated cleavage of a selection 
plasmid encoding an inducible toxic gene (Fig. 1b, Extended Data Fig. 1a). We mutagenized 
the PAM-interacting (PI) domains of wild-type and R1335Q SpCas9 and performed 
selections against an NGA PAM target site (Extended Data Fig. 1b, Online Methods). 
Sequences of surviving clones from both libraries revealed the most frequent substitutions 
were D1135V/Y/N/E, R1335Q, and T1337R (Extended Data Fig. 2a). After testing all 
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combinations of these mutations using the human cell-based EGFP disruption assay, two 
variants were chosen for further characterization because they possessed the greatest 
discrimination between NGA and NGG PAMs: D1135V/R1335Q/T1337R and D1135E/
R1335Q/T1337R (hereafter referred to as the VQR and EQR variants, respectively) (Fig. 
1c).
To define the global PAM specificity profiles of these SpCas9 variants, we used a bacterial-
based negative selection system (Fig. 1d, Extended Data Fig. 3a) similar to other methods 
previously used to identify PAM preferences of Cas98, 17. In this site-depletion assay, a 
library of plasmids bearing 6 randomized base pairs adjacent to a protospacer is tested for 
cleavage by Cas9 in E. coli (Extended Data Fig. 3b). Plasmids with PAM sequences 
refractory to Cas9 enable cell survival due to the presence of an antibiotic resistance gene, 
whereas plasmids bearing targetable PAMs are depleted from the library (Fig. 1d, Extended 
Data Fig. 3b). Sequencing the uncleaved population of plasmids enables the calculation of a 
post-selection PAM depletion value (PPDV), an estimate of Cas9 activity against those 
PAMs (post-selection frequency relative to the pre-selection frequency). Site-depletion data 
obtained with catalytically inactive Cas9 (dCas9) on two randomized PAM libraries (each 
with a different protospacer) enabled us to define what represents a statistically significant 
change in PPDV for any given PAM or group of PAMs (Extended Data Fig. 3c), and 
PPDVs observed for wild-type SpCas9 recapitulated its previously described profile of 
targetable PAMs8 (Fig. 1e).
Using the site-depletion assay, we obtained PAM specificity profiles for the VQR and EQR 
variants. The VQR variant strongly depleted sites bearing NGAN and NGCG PAMs, while 
the EQR variant appeared more specific for an NGAG PAM (Fig. 1f). The human cell EGFP 
disruption assay paralleled these results, with the VQR variant robustly cleaving sites 
bearing NGAN PAMs (with relative efficiencies NGAG>NGAT=NGAA>NGAC), and also 
sites bearing NGNG PAMs with generally lower efficiencies (Fig. 1g). Similarly, the EQR 
variant preferred NGAG to the other NGAN and NGNG PAMs in human cells, again at 
lower activities than with the VQR variant (Fig. 1g). The activities of the VQR and EQR 
variants in human cells therefore recapitulated what was observed with the bacterial site-
depletion assay and suggested that PPDVs of 0.2 (five-fold depletion) provide a reasonable 
predictive threshold for activity in human cells (Extended Data Fig. 4).
We next sought to extend the generalizability of our engineering strategy by identifying 
SpCas9 variants capable of recognizing an NGC PAM. Selections using libraries bearing 
pre-existing R1335E/T1337R and R1335T/T1337R substitutions (Online Methods) yielded 
surviving colonies harboring a variety of additional mutations (Extended Data Fig. 2b). 
Testing all possible combinations of the most common mutations using the EGFP disruption 
assay established that the quadruple mutant VRER variant (D1135V/G1218R/R1335E/
T1337R) displayed the highest activity on an NGC PAM and minimal activity on an NGG 
PAM (Fig. 1h). Analysis of the VRER variant using the site-depletion assay revealed it to be 
highly specific for NGCG PAMs (Fig. 1i). Consistent with this result, EGFP disruption 
assays revealed efficient cleavage of sites with NGCG PAMs, and inconsistent or low 
activity against NGCH and NGNG PAMs (Fig. 1j). Notably, the mutations critical for 
altering the specificity of SpCas9 are spatially oriented near the PAM (Extended Data Fig. 
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5a), and the nature and effect of the mutations imply that they are most likely gain of 
function (Extended Data Fig. 5b). For example, the T1337R mutation appears to confer a 
preference for a fourth PAM base, especially in the case of the VRER variant.
To demonstrate directly that the SpCas9 variants broaden the targeting range of SpCas9, we 
tested their activities against endogenous genes in zebrafish embryos and human cells. In 
zebrafish embryos, the VQR variant efficiently modified sites bearing NGAG PAMs (range 
of 20 to 43%, Fig. 2a) with the indels originating at the predicted cleavage sites (Extended 
Data Fig. 6). In human cells, the VQR variant robustly modified endogenous sites that 
harbored NGA PAMs (again, with a preference for NGAG>NGAT=NGAA, range of 6 to 
53%) (Fig. 2b, Extended Data Fig. 7a). Importantly, wild-type SpCas9 was unable to 
robustly alter NGA PAM sites in zebrafish and human cells (Figs. 2a, 2c), yet able to 
efficiently modify neighboring sites bearing NGG PAMs (Extended Data Fig. 7b). 
Similarly, when examining VRER variant activity at endogenous human sites with NGCG 
PAMs, we also observed robust disruption frequencies (range of 5 to 36%) (Fig. 2d). 
Consistent with the site-depletion data (Figs. 1e, 1f), the VQR variant also altered NGCG 
PAM sites while wild-type SpCas9 was unable to do so (Fig. 2d). Taken together, these 
results demonstrate that the VQR and VRER variants enable modification of previously 
inaccessible sites in zebrafish embryos and human cells, and computational analysis of the 
reference human genome reveals that they double the targeting potential of SpCas9 (Fig. 
2e). To identify target sites for the engineered variants, we have developed a web-based tool 
called CasBLASTR (http://www.CasBLASTR.org).
To determine the genome-wide specificity of the VQR and VRER SpCas9 nucleases, we 
used the recently described GUIDE-seq method7 to profile off-target cleavage events in 
human cells. The total number of detectable off-target DSBs induced by the SpCas9 variants 
in human cells (Fig. 2f) are comparable to (or, in the case of the VRER variant, perhaps 
better than) what has been previously observed with wild-type SpCas97. The off-target sites 
observed generally possess the expected PAM sequences predicted by our site-depletion 
experiments (compare Figs. 1f, 1i to Extended Data Fig. 8), and the mismatches observed in 
the off-target sites of the variants are similar to the profiles previously observed with wild-
type SpCas9 for sgRNAs targeted to non-repetitive sequences7. The stringent genome-wide 
specificity observed with the VRER variant might result from its extension of the PAM by 1 
bp, and perhaps from the relative depletion of NGCG PAMs in the human genome (Fig. 
2e)18.
Previous studies have shown that imperfect PAM recognition by SpCas9 can lead to 
recognition of non-canonical PAMs7, 8, 19–21. While engineering the VQR variant, we 
noticed that a D1135E mutant appeared to better discriminate between NGG and NGA 
PAMs compared with wild-type SpCas9 (Fig. 1c). Using the site-depletion assay to assess 
the D1135E variant, we observed a decrease in activity against non-canonical NAG, NGA, 
and NNGG PAMs relative to wild-type SpCas9, with this effect being more prominent for 
one protospacer (Fig. 3a). Improved PAM specificity was also observed in human cell EGFP 
disruption assays, where NAG and NGA PAM sites were less efficiently cleaved by 
D1135E compared to wild-type SpCas9 (Fig. 3b, mean fold-decrease in activity of 1.94). 
Importantly, wild-type and D1135E SpCas9 had comparable activities against canonical 
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NGG PAM sites when targeted to the EGFP reporter or endogenous human gene sites (mean 
fold-decrease in activity of 1.04) (Figs. 3b, Extended Data Fig. 9a, respectively). It is 
unlikely that the enhanced specificity of the D1135E variant is the result of protein 
destabilization, because titration experiments revealed no substantial differences in activity 
compared with wild-type SpCas9 (Extended Data Fig. 9b).
To more directly assess the effect of D1135E on off-target effects, we examined the 
mutation rates induced by wild-type and D1135E SpCas9 on 25 previously known off-target 
sites of three sgRNAs7, 14, 19. Deep-sequencing revealed that D1135E improved specificity 
for 19 of the 22 off-target sites with mutation frequencies above background indel rates, 
when compared to the relative mutation frequencies observed at the on-target sites (Figs. 3c, 
Extended Data Fig. 9c). Interestingly, the gains in specificity with D1135E are not restricted 
to sites with non-canonical PAMs. To more thoroughly assess the improvements in 
specificity associated with the D1135E variant, we performed GUIDE-seq using three 
different sgRNAs and observed a generalized improvement in genome-wide specificity 
relative to wild-type SpCas9 (Fig. 3d, Extended Data Figs. 9d–f). Collectively, these results 
show that the D1135E substitution increases the specificity of SpCas9.
The many Cas9 orthologues from other bacteria make attractive candidates for 
characterizing and engineering Cas9s with novel PAM specificities22, 23. To explore this, we 
determined whether two smaller-size orthologues, Streptococcus thermophilus Cas9 from 
the CRISPR1 locus (St1Cas9)24, 25 and Staphyloccocus aureus (SaCas9)23 could function 
in the bacterial selection assays. Although the PAM of St1Cas9 has previously been 
characterized as NNAGAA17, 22, 24, 25, our attempts to bioinformatically derive the SaCas9 
PAM using a previously described approach22 failed to yield a consensus sequence. 
Therefore, we used the site-depletion assay to determine the PAM for SaCas9 and, as a 
positive control, St1Cas9. For St1Cas9, we identified two novel PAMs in addition to six 
PAMs that had been previously described17, 22, 25 (Fig. 4a, Extended Data Figs. 10a, 10b). 
For SaCas9, only three PAMs were depleted greater than 5-fold in all experiments 
(NNGGGT, NNGAAT, NNGAGT, Fig. 4b), although additional PAMs were targetable 
when using the second protospacer library (Extended Data Figs. 10c, 10d). These results are 
consistent with a recent definition of SaCas9 PAM specificity23. We also found that St1Cas9 
and SaCas9 can function efficiently in the bacterial positive selection system (Fig. 4c), 
suggesting that their PAM specificities could potentially be modified by mutagenesis and 
selection.
Because not all Cas9 orthologues function efficiently outside of their native context17, 23, we 
tested whether St1Cas9 and SaCas9 can modify sites in human cells. St1Cas9 has been 
previously shown to function as a nuclease in human cells but only on four sites17, 23, 26, and 
a recently published manuscript assessed SaCas9 activity23. In EGFP disruption 
experiments, St1Cas9 displayed high activity at three of five target sites and SaCas9 
efficiently targeted eight sites (Extended Data Fig. 10e). No obvious correlation between 
activity and length of spacer was observed (Extended Data Fig. 10e, 10f). When examining 
activity on endogenous loci, St1Cas9 efficiently targeted 7 out of 11 sites (1 to 25% 
disruption; Fig. 4d), SaCas9 displayed more robust activity at 16 sites (1% to 37%; Fig. 4e), 
and again no distinct spacer length requirement was observed (Extended Data Fig. 10g). 
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Collectively, these results demonstrate that St1Cas9 and SaCas9 function in human cells, 
making them attractive candidates for engineering additional variants with novel PAM 
specificities.
The VQR and VRER variants engineered in this study enhance the opportunities to utilize 
the CRISPR-Cas9 platform to practice efficient HDR, to generate NHEJ-mediated indels in 
small genetic elements, and to exploit the requirement for a PAM to distinguish between 
different alleles in the same cell. Importantly, the VQR, VRER, and D1135E variants all 
have similar (or better) genome-wide specificities compared to wild-type SpCas9. These 
variants can be rapidly incorporated into existing and widely used SpCas9 vectors by simple 
site-directed mutagenesis, and we expect that the variants should also work with other 
previously described improvements to the SpCas9 platform (e.g., truncated sgRNAs7, 27, 
SpCas9 nickases20, 28, or dimeric FokI-dCas9 fusions29, 30). Collectively, our results 
establish engineering PAM recognition and characterization of additional Cas9 orthologues 
(as previously described)17, 22, 23 as complementary approaches to provide researchers with 
an expanded repertoire of genome-editing reagents, while also demonstrating the feasibility 
of engineering Cas9 nuclease variants with useful new properties.
Online Methods
Plasmids and oligonucleotides
DNA sequences for parent constructs used in this study can be found in Supplementary 
Information. Sequences of oligonucleotides used to generate the positive selection plasmids, 
negative selection plasmids, and site-depletion libraries are available in Supplementary 
Table 1. Sequences of all sgRNA targets in this study are available in Supplementary Table 
2. Point mutations in Cas9 were generated by PCR. For cloning purposes, please note the 
low copy number origins of these plasmids. All new plasmids described in this study will be 
deposited with the non-profit plasmid distribution service Addgene: http://
www.addgene.org/crispr-cas.
Bacterial Cas9/sgRNA expression plasmids were constructed with two T7 promoters to 
separately express Cas9 and the sgRNA. These plasmids encode human codon optimized 
versions of Cas9 for S. pyogenes (BPK764, SpCas9 sequence subcloned from JDS24614), S. 
thermophilus Cas9 from CRISPR locus 1 (MSP1673, St1Cas9 sequence modified from 
previous published description17), and S. aureus (BPK2101, SaCas9 sequence codon 
optimized from Uniprot J7RUA5). Previously described sgRNA sequences were utilized for 
SpCas931, 32 and St1Cas917, while the SaCas9 sgRNA sequence was determined by 
searching the European Nucleotide Archive sequence HE980450 for crRNA repeats using 
CRISPRfinder (http://crispr.u-psud.fr/Server/) and identifying the tracrRNA using a 
bioinformatic approach similar to one previously described33. Annealed oligos to complete 
the spacer complementarity region of the sgRNA were ligated into BsaI cut BPK764 and 
BPK2101, or BspMI cut MSP1673 (append 5’-ATAG to the spacer to generate the top oligo 
and append 5’-AAAC to the reverse compliment of the spacer sequence to generate the 
bottom oligo). A 5’-GG dinucleotide was included on all bacterial plasmid sgRNAs for 
proper expression from the T7 promoter.
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Residues 1097–1368 of SpCas9 were randomly mutagenized using Mutazyme II (Agilent 
Technologies) at a rate of ~5.2 substitutions/kilobase to generate mutagenized PAM-
interacting (PI) domain libraries. For NGA PAM selections, wild-type SpCas9 and R1335Q 
were utilized as templates for mutagenesis. For NGC PAM selections, we first designed 
Cas9 mutants bearing amino acid substitutions of R1335 that might be expected to interact 
with a cytosine (D, E, S, or T) and found no activity on an NGC PAM site using the positive 
selection system (data not shown). We then randomly mutagenized the PAM-interacting 
domain of each of these singly substituted variants but still failed to obtain surviving 
colonies in positive selections (data not shown). Because the T1337R mutation had 
increased the activities of our VQR and EQR variants, we combined this mutation with 
R1335 substitutions of A, D, E, S, T, or V, and again randomly mutagenized their PAM-
interacting domains. Selections using two of these six mutagenized libraries (bearing pre-
existing R1335E/T1337R and R1335T/T1337R substitutions) yielded surviving colonies 
harboring a variety of additional mutations (Extended Data Fig. 2b). The theoretical 
complexity of each PI domain library was estimated to be greater than 107 clones based on 
the number of transformants obtained. Positive and negative selection plasmids were 
generated by ligating annealed target site oligos into XbaI/SphI or EcoRI/SphI cut p11-lacY-
wtx115, respectively.
Two randomized PAM libraries (each with a different protospacer sequence) were 
constructed using Klenow(-exo) to fill-in the bottom strand of oligos that contained six 
randomized nucleotides directly adjacent to the 3’ end of the protospacer (see 
Supplementary Table 1). The double-stranded product was cut with EcoRI to leave EcoRI/
SphI ends for ligation into cut p11-lacY-wtx1. The theoretical complexity of each 
randomized PAM library was estimated to be greater than 106 based on the number of 
transformants obtained.
SpCas9 and variants were expressed in human cells from vectors derived from JDS24614. 
For St1Cas9 and SaCas9, the Cas9 ORFs from MSP1673 and BPK2101 were subcloned into 
a CAG promoter vector to generate MSP1594 and BPK2139, respectively. Plasmids for U6 
expression of sgRNAs (into which desired spacer oligos can be cloned) were generated 
using the sgRNA sequences described above for the SpCas9 sgRNA (BPK1520), the 
St1Cas9 sgRNA (BPK2301), and the SaCas9 sgRNA (VVT1). Annealed oligos to complete 
the spacer complementarity region of the sgRNA were ligated into the BsmBI overhangs of 
these vectors (append 5’-CACC to the spacer to generate the top oligo and append 5’-AAAC 
to the reverse complement of the spacer sequence to generate the bottom oligo). A 5’-G of 
target spacer sequences was included when designing human cell sgRNAs, for proper 
expression from the U6 promoter (and thus included in the calculation in Fig. 2e).
Bacterial-based positive selection assay for evolving SpCas9 variants
Competent E.coli BW25141(λDE3)34 containing a positive selection plasmid (with 
embedded target site) were transformed with Cas9/sgRNA-encoding plasmids. Following a 
60 minute recovery in SOB media, transformations were plated on LB plates containing 
either chloramphenicol (non-selective) or chloramphenicol + 10 mM arabinose (selective). 
Cleavage of the positive selection plasmid was estimated by calculating the survival 
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frequency: colonies on selective plates / colonies on non-selective plates (see also Extended 
Data Fig. 1).
To select for SpCas9 variants that can target novel PAMs, PI-domain mutagenized Cas9/
sgRNA plasmid libraries were electroporated into E.coli BW25141(λDE3) cells containing a 
positive selection plasmid that encodes a target site and PAM of interest. Generally ~50,000 
clones were screened to obtain between 50–100 survivors. The PI domains of surviving 
clones were subcloned into fresh backbone plasmid and re-tested in the positive selection. 
Clones that had greater than 10% survival in this secondary screen for activity were 
sequenced. Mutations observed in the sequenced clones were chosen for further assessment 
based on their frequency in surviving clones, type of substitution, proximity to the PAM 
bases in the SpCas9/sgRNA crystal structure (PDB:4UN3)12, and (in some cases) activities 
in a human cell-based EGFP disruption assay.
Bacterial-based site-depletion assay for profiling Cas9 PAM specificities
Competent E.coli BW25141(λDE3) containing a Cas9/sgRNA expression plasmid were 
transformed with negative selection plasmids harboring cleavable or non-cleavable target 
sites. Following a 60 minute recovery in SOB media, transformations were plated on LB 
plates containing chloramphenicol + carbenicillin. Cleavage of the negative selection 
plasmid was estimated by calculating the colony forming units per µg of DNA transformed 
(see also Extended Data Fig. 3).
The negative selection was adapted to determine PAM specificity profiles of Cas9 nucleases 
by electroporating each randomized PAM library into E.coli BW25141(λDE3) cells 
harboring an appropriate Cas9/sgRNA plasmid. Between 80,000–100,000 colonies were 
plated at a low density spread on LB + chloramphenicol + carbenicillin plates. Surviving 
colonies containing negative selection plasmids refractory to cleavage by Cas9 were 
harvested and plasmid DNA isolated by maxi-prep (Qiagen). The resulting plasmid library 
was amplified by PCR using Phusion Hot-start Flex DNA Polymerase (New England 
BioLabs) followed by an Agencourt Ampure XP cleanup step (Beckman Coulter 
Genomics). Dual-indexed Tru-Seq Illumina deep-sequencing libraries were prepared using 
the KAPA HTP library preparation kit (KAPA BioSystems) from ~500 ng of clean PCR 
product for each site-depletion experiment. The Dana-Farber Cancer Institute Molecular 
Biology Core performed 150-bp paired-end sequencing on an Illumina MiSeq Sequencer.
The raw FASTQ files outputted for each MiSeq run were analyzed with a Python program to 
determine relative PAM depletion. The program (see Supplementary Information) operates 
as follows: First, a file dialog is presented to the user from which all FASTQ read files for a 
given experiment can be selected. For these files, each FASTQ entry is scanned for the fixed 
spacer region on both strands. If the spacer region is found, then the six variable nucleotides 
flanking the spacer region are captured and added to a counter. From this set of detected 
variable regions, the count and frequency of each window of length 2–6 nt at each possible 
position was tabulated (see Supplementary Table 3 for the 6 nt output). The site-depletion 
data for both randomized PAM libraries was analyzed by calculating the post-selection 
PAM depletion value (PPDV): the post-selection frequency of a PAM in the selected 
population divided by the pre-selection library frequency of that PAM. PPDV analyses were 
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performed for each experiment across all possible 2–6 length windows in the 6 bp 
randomized region. The windows we used to visualize PAM preferences were: the 3 nt 
window representing the 2nd, 3rd, and 4th PAM positions for wild-type and variant SpCas9 
experiments, and the 4 nt window representing the 3rd, 4th, 5th, 6th PAM positions for 
St1Cas9 and SaCas9.
Two significance thresholds for PPDVs were determined based on: 1) a statistical 
significance threshold based on the distribution of dCas9 versus pre-selection library log 
read count ratios (see Extended Data Fig. 3c & 3d), and 2) a biological activity threshold 
based on an empirical correlation between depletion values and activity in human cells. The 
statistical threshold was set at 3.36 standard deviations from the mean PPDV for dCas9 
(equivalent to a relative PPDV of 0.85), corresponding to a normal distribution two-sided p-
value of 0.05 after adjusting for multiple comparisons (i.e. p=0.05/64). The biological 
activity threshold was set at 5-fold depletion (equivalent to a PPDV of 0.2) because this 
level of depletion serves as a reasonable predictor of activity in human cells (see also 
Extended Data Fig. 4). The 95% confidence intervals in Extended Data Fig. 4 were 
calculated by dividing the standard deviation of the mean, by the square root of the sample 
size multiplied by 1.96.
Human cell culture and transfection
U2OS cells obtained from our collaborator Toni Cathomen (Freiburg) and U2OS.EGFP 
cells harboring a single integrated copy of a constitutively expressed EGFP-PEST reporter 
gene13 were cultured in Advanced DMEM media (Life Technologies) supplemented with 
10% FBS, 2 mM GlutaMax (Life Technologies), penicillin/streptomycin, at 37 °C with 5% 
CO2. Additionally, U2OS.EGFP cells were cultured in 400 µg/ml of G418. The identity of 
U2OS and U2OS.EGFP cell lines were validated by STR profiling (ATCC) and deep 
sequencing, and cells were tested bi-weekly for mycoplasma contamination. Cells were co-
transfected with 750 ng of Cas9 plasmid and 250 ng of sgRNA plasmid (unless otherwise 
noted) using the DN-100 program of a Lonza 4D–nucleofector according to the 
manufacturer’s protocols. Cas9 plasmid transfected together with an empty U6 promoter 
plasmid was used as a negative control for spontaneous background EGFP loss for all 
human cell EGFP disruption experiments, and all engodenous gene disruption experiments 
(none of which showed detectable activity by T7E1). Target sites for endogenous gene 
experiments were selected within 200 bp of NGG sites cleavable by wild-type SpCas9 (see 
Extended Data Fig. 6a and Supplementary Table 2).
Zebrafish care and injections
Zebrafish care and use was approved by the Massachusetts General Hospital Subcommittee 
on Research Animal Care. Cas9 mRNA was transcribed with PmeI-digested JDS246 (wild-
type SpCas9) or MSP469 (VQR variant) using the mMESSAGE mMACHINE T7 ULTRA 
Kit (Life Technologies) as previously described32. All sgRNAs in this study were prepared 
according to the cloning-independent sgRNA generation method35. sgRNAs were 
transcribed by the MEGAscript SP6 Transcription Kit (Life Technologies), purified by RNA 
Clean & Concentrator-5 (Zymo Research), and eluted with RNase-free water.
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sgRNA- and Cas9-encoding mRNA were co-injected into one-cell stage zebrafish embryos. 
Each embryo was injected with ~2–4.5 nL of solution containing 30 ng/µL sgRNA and 300 
ng/µL Cas9 mRNA. The next day, injected embryos were inspected under a stereoscope for 
normal morphological development, and genomic DNA was extracted from 5 to 9 embryos.
Human cell EGFP disruption assay
EGFP disruption experiments were performed as previously described14. Transfected cells 
were analyzed for EGFP expression ~52 hours post-transfection using a Fortessa flow 
cytometer (BD Biosciences). Background EGFP loss was gated at approximately 2.5% for 
all experiments (graphically represented as a dashed red line).
T7E1 assay, targeted deep-sequencing, and GUIDE-seq to quantify nuclease-induced 
mutations
T7E1 assays were performed as previously described for human cells13 and zebrafish32. For 
U2OS.EGFP human cells, genomic DNA was extracted from transfected cells ~72 hours 
post-transfection using the Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman 
Coulter Genomics). Target loci from zebrafish or human cell genomic DNA were amplified 
using the primers listed in Supplementary Table 1. Roughly 200 ng of purified PCR product 
was denatured, annealed, and digested with T7E1 (New England BioLabs). Mutagenesis 
frequencies were quantified using a Qiaxcel capillary electrophoresis instrument (QIagen), 
as previously described for human cells13 and zebrafish32.
For targeted deep-sequencing, previously characterized on- and off-target sites7, 14, 27 were 
amplified using Phusion Hot-start Flex with the primers listed in Supplementary Table 1. 
Genomic loci were amplified for a control condition (empty sgRNA), wild-type, and 
D1135E SpCas9. An Agencourt Ampure XP cleanup step (Beckman Coulter Genomics) was 
performed prior to pooling ~500 ng of DNA from each condition for library preparation. 
Dual-indexed Tru-Seq Illumina deep-sequencing libraries were generated using the KAPA 
HTP library preparation kit (KAPA BioSystems). The Dana-Farber Cancer Institute 
Molecular Biology Core performed 150-bp paired-end sequencing on an Illumina MiSeq 
Sequencer. Mutation analysis of targeted deep-sequencing data was performed as previously 
described30. Briefly, Illumina MiSeq paired end read data was mapped to human genome 
reference GRChr37 using bwa36. High-quality reads (quality score >= 30) were assessed for 
indel mutations that overlapped the target or off-target sites. 1-bp indel mutations were 
excluded from the analysis unless they occurred within 1-bp of the predicted breakpoint. 
Changes in activity at on- and off-target sites comparing D1135E versus wild-type SpCas9 
were calculated by comparing the indel frequencies from both conditions (for rates above 
background control amplicon indel levels).
GUIDE-seq experiments were performed as previously described7. Briefly, phosphorylated, 
phosphorothioate-modified double-stranded oligodeoxynucleotides (dsODNs) were 
transfected into U2OS cells along with Cas9 and sgRNA expression plasmids, as described 
above. dsODN-specific amplification, high-throughput sequencing, and mapping were 
performed to identify genomic intervals containing DSB activity. For wild-type versus 
D1135E experiments, off-target read counts were normalized to the on-target read counts to 
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correct for sequencing depth differences between samples. The normalized ratios for wild-
type and D1135E SpCas9 were then compared to calculate the fold-change in activity at off-
target sites. To determine whether wild-type and D1135E samples for GUIDE-seq had 
similar oligo tag integration rates at the intended target site, restriction fragment length 
polymorphism (RFLP) assays were performed by amplifying the intended target loci with 
Phusion Hot-Start Flex from 100 ng of genomic DNA (isolated as described above) using 
primers listed in Supplementary Table 1. Roughly 150 ng of PCR product was digested with 
20 U of NdeI (New England BioLabs) for 3 hours at 37 °C prior to clean-up using the 
Agencourt Ampure XP kit. RFLP results were quantified using a Qiaxcel capillary 
electrophoresis instrument (QIagen) to approximate oligo tag integration rates. T7E1 assays 
were performed for a similar purpose, as described above.
Extended Data
Extended Data Figure 1. Bacterial-based positive selection used to engineer altered PAM 
specificity variants of SpCas9
a, Expanded schematic of the positive selection from Fig. 1b (left panel), and validation that 
SpCas9 behaves as expected in the positive selection (right panel). b, Schematic of how the 
positive selection was adapted to select for SpCas9 variants that have altered PAM 
recognition specificities. A library of SpCas9 clones with randomized PAM-interacting (PI) 
domains (residues 1097-1368) is challenged by a selection plasmid that harbors an altered 
PAM. Variants that survive the selection by cleaving the positive selection plasmid are 
sequenced to determine the mutations that enable altered PAM specificity.
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Extended Data Figure 2. Amino acid sequences of clones that cleave target sites bearing 
alternate PAMs in the bacterial-based positive selection system
a, Sequences of variants that survived >10% when re-tested in the positive selection assay 
against an NGA PAM site (see Online Methods). Variants were selected from libraries 
containing randomly mutagenized PAM-interacting (PI) domains (residues 1097–1368) with 
or without a starting R1335Q mutation. Sequence differences compared with wild-type 
SpCas9 are highlighted. The histogram represents the number of changes at each position 
(not counting the starting R1335Q mutation). b, Sequences of variants that survived >10% 
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when re-tested in the positive selection assay against a site containing an NGC PAM. 
Variants were selected from libraries containing randomly mutagenized PAM-interacting 
(PI) domains (residues 1097–1368) with starter mutation pairs of R1335E/T1337R or 
R1335T/T1337R. Sequence differences compared with wild-type SpCas9 (shown at the top) 
are highlighted. The histogram below illustrates the number of changes at each position (not 
counting starter mutations at R1335 or T1337).
Extended Data Figure 3. Bacterial cell-based site-depletion assay for profiling the global PAM 
specificities of Cas9 nucleases
a, Expanded schematic illustrating the negative selection from Fig. 1d (left panel), and 
validation that wild-type SpCas9 behaves as expected in a screen of sites with functional 
(NGG) and non-functional (NGA) PAMs (right panel). b, Schematic of how the negative 
selection was used as a site-depletion assay to screen for functional PAMs by constructing 
negative selection plasmid libraries containing 6 randomized base pairs in place of the PAM. 
Selection plasmids that contain PAMs cleaved by a Cas9/sgRNA of interest are depleted 
while PAMs that are not cleaved (or poorly cleaved) are retained. The frequencies of the 
PAMs following selection are compared to their pre-selection frequencies in the starting 
libraries to calculate the post-selection PAM depletion value (PPDV). c, d, A cutoff for 
statistically significant PPDVs was established by plotting the PPDV of PAMs for 
catalytically inactive SpCas9 (dCas9) (grouped and plotted by their 2nd/3rd/4th positions) for 
the two randomized PAM libraries (c). A threshold of 3.36 standard deviations from the 
mean PPDV for the two libraries was calculated (red lines in (d)), establishing that any 
PPDV deviation below 0.85 is statistically significant compared to dCas9 treatment (red 
dashed line in (c)). The gray dashed line in (c) indicates a five-fold depletion in the assay 
(PPDV of 0.2).
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Extended Data Figure 4. Concordance between the site-depletion assay and EGFP disruption 
activity
Data points represent the average EGFP disruption of the two NGAN and NGNG PAM sites 
for the VQR and EQR variants (Fig. 1g) plotted against the mean PPDV observed for library 
1 and 2 (Fig. 1f) for the corresponding PAM. The red dashed line indicates PAMs that are 
statistically significantly depleted (PPDV of 0.85, see Extended Data Fig. 3c), and the gray 
dashed line represents five-fold depletion (PPDV of 0.2). Mean values are plotted with the 
95% confidence interval.
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Extended Data Figure 5. Structural and functional roles of D1135, G1218, and T1337 in PAM 
recognition by SpCas9
a, Structural representations of the six residues implicated in PAM recognition. The left 
panel illustrates the proximity of D1135 to S1136, a residue that makes a water-mediated, 
minor groove contact to the 3rd base position of the PAM12. The right panel illustrates the 
proximity of G1218, E1219, and T1337 to R1335, a residue that makes a direct, base-
specific major groove contact to the 3rd base position of the PAM12. Angstrom distances 
indicated by yellow dashed lines; non-target strand guanine bases dG2 and dG3 of the PAM 
are shown in blue; other DNA bases shown in orange; water molecules shown in red; images 
generated using PyMOL from PDB:4UN3. b, Mutational analysis of six residues in SpCas9 
that are implicated in PAM recognition. Clones containing one of three types of mutations at 
each position were tested for EGFP disruption with two sgRNAs targeted to sites harboring 
NGG PAMs. For each position, we created an alanine substitution and two non-conservative 
mutations. S1136 and R1335 were previously reported to mediate contacts to the 3rd guanine 
of the PAM12, and D1135, G1218, E1219, and T1337 are reported in this study. EGFP 
disruption activities were quantified by flow cytometry; background control represented by 
the dashed red line; error bars represent s.e.m., n = 3.
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Extended Data Figure 6. Insertion or deletion mutations induced by the VQR SpCas9 variant at 
endogenous zebrafish sites containing NGAG PAMs
For each target locus, the wild-type sequence is shown at the top with the protospacer 
highlighted in yellow (highlighted in green if present on the complementary strand) and the 
PAM is marked as red underlined text. Deletions are shown as red dashes highlighted in 
gray and insertions as lower case letters highlighted in blue. The net change in length caused 
by each indel mutation is shown on the right (+, insertion; –, deletion). Note that some 
alterations have both insertions and deletions of sequence and in these instances the 
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alterations are enumerated in parentheses. The number of times each mutant allele was 
recovered (if more than once) is shown in brackets.
Extended Data Figure 7. Endogenous genes targeted by wild-type and evolved variants of 
SpCas9
a, Sequences targeted by wild-type, VQR, and VRER SpCas9 are shown in blue, red, and 
green, respectively. Sequences of sgRNAs and primers used to amplify these loci for T7E1 
are provided in Supplementary Tables 1 and 2. b, Mean mutagenesis frequencies detected by 
T7E1 for wild-type SpCas9 at eight target sites bearing NGG PAMs in the four different 
endogenous human genes (corresponding to the annotations in the top panel). Error bars 
represent s.e.m., n = 3.
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Extended Data Figure 8. Specificity profiles of the VQR and VRER SpCas9 variants determined 
using GUIDE-seq7
The intended on-target site is marked with a black square, and mismatched positions within 
off-target sites are highlighted. a, The specificity of the VQR variant was assessed in human 
cells by targeting endogenous sites containing NGA PAMs: EMX1 site 4, FANCF site 1, 
FANCF site 3, FANCF site 4, RUNX1 site 1, RUNX1 site 3, VEGFA site 1, and ZSCAN2. b, 
The specificity of the VRER variant was assessed in human cells by targeting endogenous 
sites containing NGCG PAMs: FANCF site 3, FANCF site 4, RUNX1 site 1, VEGFA site 1, 
and VEGFA site 2.
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Extended Data Figure 9. Activity differences between D1135E and wild-type SpCas9
a, Mutagenesis frequencies detected by T7E1 for wild-type and D1135E SpCas9 at six 
endogenous sites in human cells. Error bars represent s.e.m., n = 3; mean fold change in 
activity is shown. b, Titration of the amount of wild-type or D1135E SpCas9-encoding 
plasmid transfected for EGFP disruption experiments in human cells. The amount of sgRNA 
plasmid used for all of these experiments was fixed at 250 ng. Two sgRNAs targeting 
different EGFP sites were used; error bars represent s.e.m., n = 3. c, Targeted deep-
sequencing of on- and off-target sites for 3 sgRNAs using wild-type and D1135E SpCas9. 
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The on-target site is shown at the top, with off-target sites listed below highlighting 
mismatches to the on-target. Fold decreases in activity with D1135E relative to wild-type 
SpCas9 at off-target sites greater than the change in activity at the on-target site are 
highlighted in green; control indel levels for each amplicon are reported. d, Mean frequency 
of GUIDE-seq oligo tag integration at the on-target sites, estimated by restriction fragment 
length polymorphism analysis. Error bars represent s.e.m., n = 4. e, Mean mutagenesis 
frequencies at the on-target sites detected by T7E1 for GUIDE-seq experiments. Error bars 
represent s.e.m., n = 4. f, GUIDE-seq read-count differences between wild-type SpCas9 and 
D1135E at 3 endogenous human cell sites. The on-target site is shown at the top and off-
target sites are listed below with mismatches highlighted. In the table, a ratio of off-target 
activity to on-target activity is compared between wild-type and D1135E to calculate the 
normalized fold-changes in specificity (with gains in specificity highlighted in green). For 
sites without detectable GUIDE-seq reads, a value of 1 has been assigned to calculate an 
estimated change in specificity (indicated in orange). Off-target sites analyzed by deep-
sequencing in panel c are numbered to the left of the EMX1 site 3 and VEGFA site 3 off-
target sites
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Extended Data Figure 10. Additional PAMs for St1Cas9 and SaCas9 and activities based on 
spacer lengths in human cells
a, PPDV scatterplots for St1Cas9 comparing the sgRNA complementarity lengths of 20 and 
21 nucleotides obtained with a randomized PAM library for spacer 1 (top panel) or spacer 2 
(bottom panel). PAMs were grouped and plotted by their 3rd/4th/5th/6th positions. The red 
dashed line indicates PAMs that are statistically significantly depleted (see Extended Data 
Fig. 3c) and the gray dashed line represents five-fold depletion (PPDV of 0.2). b, Table of 
PAMs with PPDVs of less than 0.2 for St1Cas9 under each of the four conditions tested. 
PAM numbering shown on the left is the same as in Fig. 4a. c, PPDV scatterplots for 
SaCas9 comparing the sgRNA complementarity lengths of 21 and 23 nucleotides obtained 
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with a randomized PAM library for spacer 1 (top panel) or spacer 2 (bottom panel). PAM 
were grouped and plotted by their 3rd/4th/5th/6th positions. The red and gray dashed lines are 
the same as in (a). d, Table of PAMs with PPDVs of less than 0.2 for SaCas9 under each of 
the four conditions tested. PAM numbering is the same as in Fig. 4b. e, f, Human cell 
activity of St1Cas9 and SaCas9 across various spacer lengths via EGFP disruption (panel e, 
data from Figs. 4d, 4e) and endogenous gene mutagenesis detected by T7E1 (panel f, data 
from Figs. 4f, 4g). Activity for all replicates shown (n = 3 or 4); bars illustrate mean and 
95% confidence interval; number of sites per spacer length indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Evolution and characterization of SpCas9 variants with altered PAM specificities
a, Activity of wild-type and mutant SpCas9s assessed via U2OS human cell-based EGFP 
disruption. Frequencies were quantified by flow cytometry; error bars represent s.e.m., n = 
3; mean level of background EGFP loss represented by the dashed red line for this and 
subsequent panels (c, g, h, and j). b, Schematic of the positive selection assay (see also 
Extended Data Fig. 1). c, Combinatorial assembly and human cell testing of mutations 
obtained from the positive selection for SpCas9 variants that can cleave a target site 
containing an NGA PAM, using the EGFP disruption assay. d, Schematic of the negative 
selection assay, adapted to profile Cas9 PAM specificity by generating a library of plasmids 
that contain a randomized sequence adjacent to the 3’ end of the protospacer (see also 
Extended Data Fig. 3b). e, Scatterplot of the post-selection PAM depletion values (PPDVs) 
of wild-type SpCas9 with two randomized PAM libraries (each with a different 
protospacer). PAMs are plotted by their 2nd/3rd/4th positions. The red dashed line indicates 
statistically significant depletion (obtained from a dCas9 control experiment, see Extended 
Data Fig. 3c), and the gray dashed line represents five-fold depletion (PPDV of 0.2). f, 
PPDV scatterplots for the VQR and EQR variants. g, EGFP disruption frequencies for wild-
type, VQR, and EQR SpCas9 on sites with NGAN and NGNG PAMs. h, Combinatorial 
assembly and human cell testing of mutations obtained from the positive selection for 
SpCas9 variants that can cleave a target site containing an NGC PAM, using the EGFP 
disruption assay. i, PPDV scatterplot for the VRER variant. j, EGFP disruption frequencies 
for wild-type and VRER SpCas9 on sites with NGCN and NGNG PAMs.
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Figure 2. SpCas9 PAM variants robustly modify endogenous sites in zebrafish embryos and 
human cells
a, Mutagenesis frequencies in zebrafish embryos induced by wild-type or VQR SpCas9 at 
endogenous gene sites bearing NGAG PAMs. Mutation frequencies were determined using 
the T7E1 assay; n.d., not detectable by T7E1; error bars represent s.e.m., n = 5 to 9 embryos. 
b, Endogenous gene disruption activity of the VQR variant quantified by T7E1 assay. Error 
bars represent s.e.m., n = 3. c, Endogenous gene disruption activity of wild-type SpCas9 
against NGA PAM sites quantified by T7E1 assay, where VQR data is re-presented from 
panel b for ease of comparison. Error bars represent s.e.m., n = 3. d, Mutation frequencies of 
wild-type, VRER, and VQR SpCas9 at endogenous human cell sites containing NGCG 
PAMs quantified by T7E1 assay; error bars represent s.e.m., n = 3. e, Representation of the 
number sites in the human genome with 20 nt spacers targetable by wild-type, VQR, and 
VRER SpCas9. The 5’-G is included for expression from a U6 promoter. f, Number of off-
target cleavage sites identified by GUIDE-seq for the VQR and VRER variants using 
sgRNAs from panels b and d.
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Figure 3. A D1135E mutation improves the PAM recognition and spacer specificity of SpCas9
a, PPDV scatterplots for wild-type and D1135E SpCas9 for the two randomized PAM 
libraries. PAMs are plotted by their 2nd/3rd/4th positions, and wild-type data is the same as 
shown in Fig. 1d for ease of comparison. The red dashed line indicates PAMs that are 
statistically significantly depleted (see Extended Data Fig. 3c), and the gray dashed line 
indicates five-fold depletion (PPDV of 0.2). b, EGFP disruption activities of wild-type and 
D1135E SpCas9 on sites that contain canonical and non-canonical PAMs in human cells. 
Disruption frequencies were quantified by flow cytometry; mean background level of EGFP 
loss represented by the dashed red line; error bars represent s.e.m., n = 3; fold change in 
activity is shown. c, Summary of targeted deep-sequencing data demonstrating specificity 
gains at off-target sites when using D1135E (see also Extended Data Fig. 9c). d, Summary 
of GUIDE-seq detected changes in specificity between wild-type and D1135E at off-target 
sites (see also Extended Data Fig. 9f). Estimated fold-gain in specificity at sites without 
read-counts for D1135E are not plotted (see Extended Data Fig. 8c).
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Figure 4. Characterization of St1Cas9 and SaCas9 in bacteria and human cells
a, b, PPDV scatterplots for St1Cas9 (panel a) and SaCas9 (panel b), with PAMs plotted by 
their 3rd/4th/5th/6th positions. The red dashed line indicates PAMs that are statistically 
significantly depleted (Extended Data Fig. 3c), and the gray dashed line represents five-fold 
depletion (PPDV of 0.2); α, PAM previously predicted by a bioinformatic approach25; β, 
PAMs previously identified under stringent experimental conditions17; *, novel PAMs 
discovered in this study; γ, PAMs previously identified under moderate experimental 
conditions17 c, Survival percentages of St1Cas9 and SaCas9 in the bacterial positive 
selection when challenged with selection plasmids that harbor different target sites and 
PAMs. d, e, Mutation frequencies of St1Cas9 (panel d) and SaCas9 (panel e) quantified by 
T7E1 assay at sites in four endogenous human genes. Error bars represent s.e.m., n = 3; n.d., 
not detectable by T7E1.
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